The Hidden Cost of Evergreening: How Strategic Patent Tactics Are Stalling Generic Innovation and Keeping Prices Sky-High
In the relentless world of pharmaceuticals, innovation is often celebrated as the lifeblood of progress. But lurking beneath the s…

In the relentless race for pharmaceutical dominance, patent strategies have become as critical as the drugs themselves. But what happens when the traditional boundaries of patent law are pushed to their limits? Enter the concept of "chaining injun…

In the complex labyrinth of pharmaceutical innovation, patent thickets have long been a formidable barrier—stifling competition, delaying access to life-saving drugs, and inflating healthcare costs. For decades, these dense webs of overlapping patents …

In the high-stakes world of pharmaceutical innovation, every advantage counts. Yet, as the landscape becomes increasingly crowded with generics, the race to secure market dominance hinges on a nuanced understanding of exclusivity periods—particularly t…

In the fiercely competitive world of pharmaceutical innovation, securing a patent for a new drug is only half the battle. The real challenge lies in navigating the complex, often treacherous waters of the FDA’s patent challenge process—particularly Par…

In the high-stakes world of biopharmaceuticals, understanding where value truly resides can make or break investment strategies. For years, industry insiders have navigated a complex maze of innovation, regulation, and market dynamics—often without a c…

In the high-stakes world of pharmaceutical innovation, China’s evolving patent landscape is akin to navigating a treacherous dragon’s den—full of opportunity, but fraught with peril for the unprepared. As global pharma giants and biotech startups alike…

In the high-stakes world of pharmaceutical market access, timing isn’t just everything—it’s the difference between market dominance and missed opportunities. Yet, many teams still grapple with a critical question: Is the drug patent still in force?
Im…

In the high-stakes world of pharmaceuticals, innovation is often hailed as the lifeblood of progress. But lurking beneath the surface of blockbuster drug pipelines is a strategic play that’s reshaping the industry’s landscape: evergreening.
The Proble…

The Orphan Drug Paradox: How Generics Can Unlock Rare Disease Markets — And Why Pharma Must Rethink Its Strategy
Imagine investing billions into developing a groundbreaking orphan drug, only to face a paradox: the very rarity that makes your drug inval…